Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia: Difference between revisions
Aysha Aslam (talk | contribs) (Created page with "__NOTOC__ {{Supraventricular tachycardia}} {{CMG}} {{AE}}{{AA}} ==Overview== ==Management of Multifocal Atria Tachycardia== ==References== {{Reflist|2}}") |
Aysha Aslam (talk | contribs) |
||
(4 intermediate revisions by the same user not shown) | |||
Line 3: | Line 3: | ||
{{CMG}} {{AE}}{{AA}} | {{CMG}} {{AE}}{{AA}} | ||
==Overview== | ==Overview== | ||
Intravenous metoprolol or verapamil can be useful for acute treatment in patients with MAT. Oral [[verapamil]] or diltiazem is reasonable for ongoing management in patients with recurrent symptomatic MAT.<ref name="pmid26409259">{{cite journal| author=Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ et al.| title=2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2016 | volume= 67 | issue= 13 | pages= e27-e115 | pmid=26409259 | doi=10.1016/j.jacc.2015.08.856 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26409259 }} </ref> | |||
==Management of Multifocal Atria Tachycardia== | ==Management of Multifocal Atria Tachycardia== | ||
2015 AHA recommendations for the acute and ongoing management of [[multifocal atrial tachycardia]] are described below:<ref name="pmid26409259">{{cite journal| author=Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ et al.| title=2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2016 | volume= 67 | issue= 13 | pages= e27-e115 | pmid=26409259 | doi=10.1016/j.jacc.2015.08.856 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26409259 }} </ref> | |||
===Acute treatment of Multifocal Atria Tachycardia=== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Intravenous metoprolol or verapamil can be useful for acute treatment in patients with MAT.<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | |||
|} | |||
===Management of ongoing Multifocal Atria Tachycardia=== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Oral [[verapamil]] <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> or diltiazem <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> is reasonable for ongoing management in patients with recurrent symptomatic MAT<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B-NR, C-LD]])'' <nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.'''[[Metoprolol]] is reasonable for ongoing management in patients with recurrent symptomatic MAT ( <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | |||
|- | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Latest revision as of 15:51, 27 October 2016
Supraventricular tachycardia Microchapters |
Differentiating Among the Different Types of Supraventricular Tachycardia |
---|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
Diagnosis |
Treatment |
2015 ACC/AHA Guideline Recommendations |
Case Studies |
Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia On the Web |
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia |
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Intravenous metoprolol or verapamil can be useful for acute treatment in patients with MAT. Oral verapamil or diltiazem is reasonable for ongoing management in patients with recurrent symptomatic MAT.[1]
Management of Multifocal Atria Tachycardia
2015 AHA recommendations for the acute and ongoing management of multifocal atrial tachycardia are described below:[1]
Acute treatment of Multifocal Atria Tachycardia
Class IIa |
"1.Intravenous metoprolol or verapamil can be useful for acute treatment in patients with MAT."(Level of Evidence: C-LD) " |
Management of ongoing Multifocal Atria Tachycardia
Class IIa |
"1.Oral verapamil "(Level of Evidence: B-NR) " or diltiazem "(Level of Evidence: C-LD) " is reasonable for ongoing management in patients with recurrent symptomatic MAT"(Level of Evidence:B-NR, C-LD) " |
"2.Metoprolol is reasonable for ongoing management in patients with recurrent symptomatic MAT ( "(Level of Evidence: C-LD) " |
References
- ↑ 1.0 1.1 Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ; et al. (2016). "2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society". J Am Coll Cardiol. 67 (13): e27–e115. doi:10.1016/j.jacc.2015.08.856. PMID 26409259.